Overview

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study is now completed
Phase:
Phase 3
Details
Lead Sponsor:
Arpida AG
Treatments:
Iclaprim
Linezolid